



John Maraganore

Senior Advisor

Region: 1

Office Location: New York

Dr. John Maraganore is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm's investment teams and portfolio companies in the Life Sciences sector. Since 2002, Dr. Maraganore has served as the CEO of Alnylam, a biopharmaceutical company focused on RNAi therapeutics. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company's product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

Current Board Affiliations

Agios Pharmaceuticals, *Board Member*

Biotechnology Industry Organization (BIO), *Board Member, Executive Committee*

Education

University of Chicago, *M.Sc., Ph.D., Biochemistry and Molecular Biology*